Lenalidomide for active IgG4-related disease
Part of Immune system & allergy clinical trials.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with IgG4-related disease (IgG4-RD), a condition that causes inflammation and swelling in various organs.
- Your disease is currently active, meaning you have symptoms like swelling or pain that are not well controlled.
- You have the 'proliferative' form of the disease (where tissues grow or swell), not the fibrotic (scarring) form.
- You are willing to avoid pregnancy for 18 months and use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an herbal medicine (Tripterygium wilfordii) and the steroid prednisone to see if it helps control symptoms of IgG4-related disease, a condition where the immune system attacks your own organs. The study aims to find a more effective or safer treatment option.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
This trial tests a drug called sirolimus (which helps calm the immune system) for people with active IgG4-related disease. It may help reduce symptoms like swelling and pain if your current treatments are not working well.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This study tests a new type of cell therapy (CAR-NK) that uses your own immune cells to target and attack the cells causing your IgG4-related disease. It may help people whose disease has not improved with standard treatments.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.